Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
US-2024252425-A1 · Aug 1, 2024 · US
PAR-4 agonists for the treatment of cancer
US11129836B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11129836-B2 |
| Application number | US-201916420554-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 23, 2019 |
| Priority date | Jun 28, 2016 |
| Publication date | Sep 28, 2021 |
| Grant date | Sep 28, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed herein are methods of treating cancers by administration of a PAR-4 agonist.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating cancer, comprising increasing expression of prostate apoptosis response 4 in a patient having cancer by administering one or more anti-cancer agents consisting of cefuroxime, a pharmaceutically acceptable salt or prodrug thereof, in combination with an anti-cancer agent selected from the group consisting of ado-trastuzumab, ado-transtuzumab emtansine, alemtuzumab, atezolizumab, bevacizumab, blinatumomab, brentuximab vedotin, cetuximab, daratumumab, denosumab, dinutuximab, elotuzumab, gemtuzumab, gemtuzumab ozogamicin, ipilimumab, ibritumomab tiuxetan, necitumumab, nivolumab, obinutuzumab, ofatumumab, pantitumumab, pembrolizumab, pertuzumab, ramucirumab, rituximab, siltuximab, tositumomab, trastuzumab, vemurafenib, and combinations thereof. 2. The method according to claim 1 , wherein the cefuroxime, a pharmaceutically acceptable salt or prodrug thereof, is administered in combination with a monoclonal antibody selected from ado-trastuzumab, and ado-trastuzumab emtansine. 3. The method according to claim 1 , wherein the cefuroxime prodrug comprises cefuroxime axetil. 4. The method according to claim 1 , further comprising administering ionizing radiation to the patient, performing a surgical intervention on the patient, or a combination thereof. 5. The method according to claim 4 , wherein the cefuroxime is administered for a period of at least one week prior to commencing radiation treatment or surgical intervention. 6. The method according to claim 1 , wherein the cefuroxime and additional anti-cancer agent are administered in an intermittent dosing regimen. 7. The method according to claim 1 , wherein the cefuroxime and additional anti-cancer agent are administered simultaneously. 8. The method according to claim 1 , wherein the cefuroxime and additional anti-cancer agent are administered separately.
Assignees
Inventors
Classifications
Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title
- A61K31/546Primary
containing further heterocyclic rings, e.g. cephalothin · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
against tumor tissues, cells, antigens · CPC title
Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11129836B2 cover?
- Disclosed herein are methods of treating cancers by administration of a PAR-4 agonist.
- Who is the assignee on this patent?
- Cipla Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K31/546. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).